Compare · GLP-1 agonist
Semaglutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Evidence | 10/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.
Tirzepatide
Tirzepatide is a once-a-week injectable peptide. You may know it by its brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Most of the compounds we write about here have thin evidence behind them. This one is different: it has been tested in large,…